LOGIN
SABER-Bupivacaine for Post-Operative Pain and Opioid Consumption for Subacromial Decompression
July 2022
SABER-Bupivacaine for Post-Operative Pain and Opioid Consumption for Subacromial Decompression
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1
SABER-Bupivacaine Reduces Postoperative Pain and Opioid Consumption After Arthroscopic Subacromial Decompression: A Randomized, Placebo-Controlled Trial
J Am Acad Orthop Surg Glob Res Rev . 2022 May 1;6(5).Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
One hundred and seven patients undergoing an arthroscopic subacromial decompression (ASD) surgery were randomized (in a 2:1:1 ratio) to receive either sucrose acetate isobutyrate extended-release (SABER) bupivacaine (n=53), SABER-placebo (n=25), or bupivacaine HCl (n=29) to minimize post-operative pain and opioid consumption. The primary outcomes of this trial were to assess pain scores and analge...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.